Green Cross Corp Asset Resilience Ratio
Green Cross Corp asset resilience ratio. Green Cross Corp (006280) has an Asset Resilience Ratio of 0.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Green Cross Corp (006280) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Green Cross Corp (2003–2024)
Asset resilience ratio of Green Cross Corp from 2003 to 2024. This chart shows how Green Cross Corp's Asset Resilience Ratio has changed over time. Read 006280 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Green Cross Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 006280 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩4.43 Billion | 0.14% |
| Total Liquid Assets | ₩4.43 Billion | 0.14% |
Asset Resilience Insights
- Limited Liquidity: Green Cross Corp maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Green Cross Corp Industry Peers by Asset Resilience Ratio
Compare Green Cross Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Green Cross Corp Asset Resilience Ratio by Year (2003–2024)
Green Cross Corp asset resilience ratio by year from 2003 to 2024. The table below shows the annual Asset Resilience Ratio data for Green Cross Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | ₩1.43 Billion ≈ $970.18K |
₩2.74 Trillion ≈ $1.86 Billion |
-0.17pp |
| 2023-12-31 | 0.22% | ₩5.80 Billion ≈ $3.93 Million |
₩2.64 Trillion ≈ $1.79 Billion |
-0.06pp |
| 2022-12-31 | 0.27% | ₩6.94 Billion ≈ $4.70 Million |
₩2.53 Trillion ≈ $1.71 Billion |
-0.41pp |
| 2021-12-31 | 0.69% | ₩16.88 Billion ≈ $11.44 Million |
₩2.46 Trillion ≈ $1.67 Billion |
-0.39pp |
| 2020-12-31 | 1.08% | ₩23.21 Billion ≈ $15.73 Million |
₩2.15 Trillion ≈ $1.46 Billion |
-1.12pp |
| 2019-12-31 | 2.20% | ₩43.07 Billion ≈ $29.19 Million |
₩1.96 Trillion ≈ $1.33 Billion |
+1.61pp |
| 2018-12-31 | 0.59% | ₩10.11 Billion ≈ $6.85 Million |
₩1.72 Trillion ≈ $1.17 Billion |
+0.57pp |
| 2017-12-31 | 0.02% | ₩268.03 Million ≈ $181.64K |
₩1.70 Trillion ≈ $1.15 Billion |
-3.87pp |
| 2016-12-31 | 3.89% | ₩60.28 Billion ≈ $40.85 Million |
₩1.55 Trillion ≈ $1.05 Billion |
-0.04pp |
| 2015-12-31 | 3.93% | ₩55.58 Billion ≈ $37.67 Million |
₩1.42 Trillion ≈ $959.01 Million |
-0.59pp |
| 2014-12-31 | 4.51% | ₩60.05 Billion ≈ $40.70 Million |
₩1.33 Trillion ≈ $901.56 Million |
+2.75pp |
| 2013-12-31 | 1.76% | ₩19.43 Billion ≈ $13.16 Million |
₩1.10 Trillion ≈ $748.34 Million |
+1.04pp |
| 2012-12-31 | 0.71% | ₩6.82 Billion ≈ $4.62 Million |
₩954.38 Billion ≈ $646.77 Million |
-5.46pp |
| 2011-12-31 | 6.17% | ₩53.09 Billion ≈ $35.98 Million |
₩860.35 Billion ≈ $583.05 Million |
-7.78pp |
| 2010-12-31 | 13.95% | ₩103.44 Billion ≈ $70.10 Million |
₩741.30 Billion ≈ $502.37 Million |
+13.94pp |
| 2006-12-31 | 0.02% | ₩62.39 Million ≈ $42.28K |
₩362.68 Billion ≈ $245.78 Million |
-0.48pp |
| 2005-12-31 | 0.50% | ₩1.48 Billion ≈ $1.00 Million |
₩296.73 Billion ≈ $201.09 Million |
-0.30pp |
| 2004-12-31 | 0.80% | ₩2.00 Billion ≈ $1.35 Million |
₩250.79 Billion ≈ $169.96 Million |
-2.36pp |
| 2003-12-31 | 3.16% | ₩2.78 Billion ≈ $1.89 Million |
₩88.06 Billion ≈ $59.68 Million |
-- |
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more